European Commission Approves Biosimilar Imraldi for Crohn’s Disease and Ulcerative Colitis

European Commission Approves Biosimilar Imraldi for Crohn’s Disease and Ulcerative Colitis
The European Commission has approved Imraldi, an adalimumab biosimilar referencing AbbVie’s Humira — making the medication available to treat the same therapeutic indications as Humira, including Crohn’s disease, pediatric Crohn’s disease and ulcerative colitis. The Aug. 24 decision followed a positive recommendation by the European Medicines Agency’s Committee for Medicinal Products for Human Use, released in June.

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *